Aurora Cannabis Announces Fiscal 2023 First Quarter Results

EDMONTON, AB, Nov. 10, 2022 /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: AC) | (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the fiscal first quarter ended September 30, 2022. As a reminder, Fiscal 2023 will be comprised of three quarters, with the new fiscal year end being March 31, 2023.

“We are quickly approaching our positive Adjusted EBITDA goal and are on track to achieve up to $170 million in annualized cost savings by December 31, 2022, having already realized $140 million through Q1 2023. Our strengthened balance sheet and strong cash position has facilitated early repurchases of convertible debt of approximately US$160 million in 2022. Through profitable growth opportunities, particularly in our high-margin global medical cannabis business where we remain the #1 Canadian LP in revenues, disciplined capital deployment, and the completion of our cost structure rationalization, we are well-positioned to enhance the long-term value of our differentiated global cannabis company,” stated Miguel Martin, Chief Executive Officer of Aurora.

“International medical cannabis net revenues were slightly uneven in Q1 2023, characteristic of rapidly developing markets. However, the long-term growth trajectory remains solid for our unique, portable, and profitable international medical program. We continue to identify areas of profitability and growth within the Canadian adult recreational segment, even in the face of a challenging environment, and are proud to have introduced a significant number of new products this fall that will benefit both our adult recreational customers and medical patients,” he concluded.

First Quarter 2023 Highlights
(Unless otherwise stated, comparisons are made between fiscal Q1 2023, Q4 2022, and Q1 2022 results and are in Canadian dollars)

Medical Cannabis:

• Medical cannabis net revenue¹ was $31.6 million, a 14% decrease from the prior quarter and a 23% decrease from the prior year period, delivering 64% of Aurora’s Q1 2023 consolidated net revenue¹ and 86% of Adjusted gross profit before fair value (FV) adjustments¹.
  
  
  
• The decrease in net revenue¹ from Q4 was primarily attributable to timing of shipments into certain international markets during the prior quarter, with sales expected to normalize in Q2 2023. The decrease from the prior year quarter was driven by $7.9 million of sales to Israel and a strategic choice to shift our Canadian medical business towards the higher margin insured patient base.
  
  
  
• Adjusted gross margin before FV adjustments on medical cannabis net revenue¹ was 67% compared to 62% sequentially and 64% in the prior year period. The continued strength of the Company’s medical adjusted gross margins¹ reflect the direct-to-patient model in Canada and sustained presence in the high margin international medical business. In addition, the Company reduced production costs by 4% while increasing production volumes by 11%, as compared to the prior quarter, which are direct impacts being realized from the asset consolidations completed over the past year.

Consumer Cannabis:

• Consumer cannabis net revenue¹ was $13.7 million, a 9% increase from the prior quarter and a 28% decrease from the prior year period.
  
  
  
• The increase in net revenue¹ from Q4 was primarily due to a full quarter of Thrive consumer cannabis net revenues¹, partially offset by supply and ordering disruptions from a cyberattack at the Ontario Cannabis Store and store closures due to an employee strike at BC Cannabis Stores. The decrease from the prior year quarter was attributable to a reduction in the volumes sold of discount, low-margin brands, and replaced with premium higher-margin brands as Aurora management considers gross profit to be as important as revenue, and only participates in Canadian consumer market segments that allow for reasonably positive gross or contribution margins.
  
  
  
• Adjusted gross margin before FV adjustments on consumer cannabis net revenue¹ was 25% for the three months ended September 30, 2022, compared to 26% in the prior quarter and 32% in the comparable prior year period. The decrease of 1% from Q4 2022 and 7% from Q1 2022 were due primarily to higher packaging volumes in Q1 2022, which reduced average cost of goods sold in that period.

Selling, General and Administrative (“SG&A”):

• SG&A, including Research and Development (“R&D”), was $43.8 million in Q1 2023 which includes $9.3 million of restructuring, non-recurring, and out-of-period costs, and $1.1 million in pre-revenue market development costs. Excluding the non-routine items noted above, SG&A and R&D continued to be well controlled and declining at $33.4 million during Q1 2023 versus $37.8 million in the prior quarter and $42.9 million in the prior year period, presented on a comparable basis. SG&A remains at the lowest level in four years.

Consolidated:

• Total net revenue1 for fiscal Q1 2023 was $49.3 million, compared to $50.2 million in the previous quarter. Total cannabis net revenue¹ was $46.0 million, as compared to the prior quarter total cannabis net revenue¹ of $50.2 million and $60.1 million in the prior year period. The decrease was primarily driven by timing of shipments into certain international markets during the prior quarter and $7.9 million of sales to Israel in Q1 2022 and a strategic choice to shift our Canadian medical business towards the higher margin insured patient base.
  
  
  
• The Bevo business contributed $3.3 million of net revenues¹, which represents just over one month of net revenues¹. It is expected that the Bevo business will generate predictable revenues, with some seasonality, in the near-term. As Bevo repurposes the Aurora Sky facility, which is expected to greatly increase production capability, extend shipping range, and access new regional greenhouse demand in Canada and the United States, Bevo revenue is expected to increase over the longer term.
  
  
  
• Excluding the impact of the non-core bulk wholesales, adjusted gross margin before fair value adjustments on cannabis net revenue¹ for Q1 2023 remained strong and steady, and well above the industry average, at 54% compared to 52% in Q4 2022 and 54% in Q1 2022.
  
  
  
• Adjusted EBITDA¹ loss decreased to $8.7 million in Q1 2023 versus $11.6 million in Q4 2022 and $11.0 million in the prior year period. The decrease in Adjusted EBITDA loss, as compared to the prior quarter and the same period in the prior year is primarily attributable to reductions in SG&A and improvement in adjusted gross margin before fair value adjustments.

Net Loss:
Net loss for the three months ended September 30, 2022 was $51.9 million compared to $618.8 million in the prior quarter and $11.9 million for the same period in the prior year. The decrease in net loss of $566.9 million from the prior quarter was primarily due to $536.2 million in non-cash impairment charges recognized in Q4 2022. The increase in net loss of $40.0 million from the same period in the prior year was primarily due to a $35.7 million net unrealized fair value gain on derivative instruments recognized in Q1 2022, compared to a net unrealized loss of $0.9 million recognized in Q1 2023 and an increase in non-cash inventory and biological asset fair value impairment charges of $1.9 million mainly driven from management’s change in intended use of certain excess bulk flower.

Fiscal Q2 2023 Expectations:
The Company expects to achieve its goal of reaching Adjusted EBITDA profitability by December 31, 2022. Having resolved the negative impact of certain cultivar supply and wholesale distribution disruptions affecting our European medical and Canadian consumer business units respectively in fiscal Q1 2023, the Company expects cannabis revenue for fiscal Q2 2023 to be largely similar to fiscal Q4 2022. Fiscal Q2 2023 will represent the first full quarter contribution of revenue and positive Adjusted EBITDA from Bevo, albeit on a seasonally affected basis with the stronger contribution quarters expected from January to June and October to December being historically the weakest contribution quarter. Furthermore, the Company expects Adjusted Gross Margins to be consistent with fiscal Q1 2023 and expects to achieve its previously stated objective of a quarterly SG&A expense run rate below $30 million by December 31, 2022.

Operational Efficiency Plan, Balance Sheet Strength, & Cash Use:
Aurora has previously identified annualized cash savings of up to $170 million under this transformation program by December 30, 2022, split evenly between costs of goods sold (“COGS”) and SG&A. Projected COGS savings include the repurposing of the Aurora Sky facility in Edmonton. These cash savings are reflected in our P&L either as they occur within SG&A savings, or as inventory is drawn down for production-related savings.

Aurora has one of the strongest balance sheets in the Canadian Cannabis industry with approximately $393 million of cash, including $58 million in restricted cash as of November 9, 2022, and access to significant capacity under a base shelf prospectus filed on March 30, 2021 (the “2021 Shelf Prospectus”), including US$156.8 million remaining securities for sale under the 2021 at-the-market (ATM) program (the “ATM Program”). Subsequent to September 30, 2022, the Company issued 23.7 million common shares under the ATM Program for gross proceeds $40.2 million (US $29.4 million). At management’s discretion, Aurora may sell shares under the ATM Program from time to time to be utilized for strategic purposes.

On October 7, 2022, the Company repurchased a total of $31.5 million (US $23.0 million) in principal amount of convertible senior notes due 2024 (“Senior Notes”) at a total cost, including accrued interest, of $30.0 million (US $21.8 million). The purpose of the transaction, which represents a repurchase of a portion of the Notes at a 5.45% discount to par value, was to reduce the Company’s debt and annual cash interest costs. Annual cash interest savings from the repurchases of Notes made from Q3 2022 to date now total approximately $11.9 million (US$8.7 million).

The Company continues to materially improve cash use, as outlined in the following table:

Key Quarterly Financial and Operating Results

Conference Call

Aurora will host a conference call today, Thursday, November 10, 2022, to discuss these results. Miguel Martin, Chief Executive Officer, and Glen Ibbott, Chief Financial Officer, will host the call starting at 5:00 p.m. Eastern time | 3:00 p.m. Mountain Time. A question-and-answer session will follow management’s presentation.

Conference Call Details

This weblink has also been posted to the Company’s “Investor Info” link at https://investor.auroramj.com/ under “News & Events”.

About Aurora

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult-use brand portfolio includes Aurora Drift, San Rafael ’71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms, North America’s leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn.

Aurora’s common shares trade on the NASDAQ and TSX under the symbol “ACB”.

Forward Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include, but are not limited to, statements with respect to:

• pro forma measures including revenue, cash flow, Adjusted gross margin before fair value adjustments, and expected SG&A run-rates;
• the Company’s ability to execute on its business transformation plan, and path and timing to achieve Adjusted EBITDA profitability;
• anticipated cost savings and planned cost efficiencies, including the execution of the Company’s costs savings plan;
• future growth opportunities and the Company’s long-term growth trajectory;
• the introduction of a new range of products to the market and associated benefits;
• expectations for fiscal Q2 2023, including with respect to revenue, adjusted gross margins and SG&A expense run rate;
• the acquisition of the controlling interest in Bevo and the expected impact on revenue, as well as the repurposing of the Aurora Sky facility and the expected associated increase in Bevo’s production capacity and revenue; and
• future utilization of the ATM facility and the planned use of proceeds.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management’s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management’s estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 30, 2022 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Non-GAAP Measures

This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed “Non-GAAP Measures”). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures in this news release include “adjusted EBITDA”, “net revenue”, “adjusted gross profit before FV adjustments” and “adjusted gross margin before FV adjustments”.

For an explanation of each measure to related comparable financial information presented in the consolidated financial statements prepared in accordance with IFRS, refer to the section of the Company’s management’s discussion and analysis for the years ended September 30, 2022 and 2021 (the “MD&A”) entitled “Cautionary Statement Regarding Certain Non-GAAP Performance Measures”, which is incorporated by reference into this news release. A copy of the MD&A is available under the Company’s profile on SEDAR at www.sedar.com.

Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company’s operating results, underlying performance and prospects in a manner similar to Aurora’s management. Accordingly, the Non-GAAP Measures included in this news release are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

Net Revenue, Adjusted Gross Profit and Margin

Net revenue, adjusted gross profit before FV adjustments and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:

Adjusted EBITDA

Adjusted EBITDA is a Non-GAAP Measure and can be reconciled with net income, the most directly comparable GAAP financial measure, as follows:

SOURCE Aurora Cannabis Inc.

Company Relationship Disclosure

T420 is responsible for the T420 opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and T420 does not undertake to confirm or substantiate or be responsible for such information provided by other parties.

Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.

This article contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories